Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 19/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 19/20 | 0.76 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8483557 | 0.90 | ESR1 (0.81) | ESR1ESR2HSP90AA1 | |
| SCHEMBL3922447 | 0.86 | ESR1 (1.00) | ESR1ESR2HSP90AA1 | |
| SCHEMBL22804807 | 0.84 | ESR1 (0.53) | ESR1ESR2HSP90AA1 | |
| SCHEMBL25341436 | 0.81 | ESR1 (0.59) | ESR1ESR2HSP90AA1 | |
| SCHEMBL29509843 | 0.81 | ESR1 (0.59) | ESR1ESR2HSP90AA1 | |
| SCHEMBL5378603 | 0.81 | ESR1 (0.76) | ESR1ESR2HSP90AA1 | |
| SCHEMBL4221887 | 0.80 | MEN1 (0.55) | ESR1ESR2 | |
| SCHEMBL21067665 | 0.80 | ESR1 (0.66) | ESR1ESR2HSP90AA1 | |
| SCHEMBL4745564 | 0.77 | ESR1 (0.81) | ESR1ESR2HSP90AA1 | |
| SCHEMBL7875599 | 0.77 | ESR1 (0.53) | ESR1ESR2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| EP-1708996-B1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1708996-A1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073189-A1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-11 | — | — | WO | disclosed |
| US-5856503-A | ANTICHOLESTEROL AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1999-01-05 | — | — | US | disclosed |
| EP-0778271-A2 | Aminoalkyl-substituted benzo-heterocyclic compounds | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPK7 | ESR1 4290/4885ESR2 1899/4885HSP90AA1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.